Three clinical cases of nonrespiratory acidosis in kidney transplant recipients receiving anti-CMV therapy

Annals of Transplantation

Volumn 17, Issue 2, 2012, Pages 135-140

  Kabat Koperska, Joanna ^a   Kedzierska, Karolina ^a   Gołembiewska, Edyta ^a   Marchelek Myśliwiec, Małgorzata ^a   Dutkiewicz, Grazyna ^a   Ciechanowski, Kazimierz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Cytomegalovirus; Ganciclovir; Kidney Transplantation; Nonrespiratory acidosis; Valganciclovir

Indexed keywords

BICARBONATE; CREATININE; EVEROLIMUS; GANCICLOVIR; IMMUNOGLOBULIN G; LACTIC ACID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TACROLIMUS; VALGANCICLOVIR;

ABDOMINAL PAIN; ACID BASE BALANCE; ACUTE GRAFT REJECTION; ANTIHYPERTENSIVE THERAPY; ANTIVIRAL THERAPY; ARTICLE; BLOOD PH; CARBON DIOXIDE TENSION; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GLOMERULONEPHRITIS; CHRONIC PYELONEPHRITIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DYSPNEA; EPIGASTRIC PAIN; GENERAL CONDITION DETERIORATION; GRAFT RECIPIENT; HEART ARREST; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HIATUS HERNIA; HOSPITALIZATION; HUMAN; HYDRONEPHROSIS; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; METABOLIC ACIDOSIS; NEPHRECTOMY; OBESITY; OXYGEN TENSION; PERISTALSIS; TACHYPNEA; TREATMENT DURATION;

ACIDOSIS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84863558430     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Marcen R: Immunosupressive Drugs In Kidney Transplantation. Drugs, 2009; 69(16): 2227-43
2. Durlik M: Zalecenia Polskiego Towarzystwa Transplantacyjnego Krajowego Konsultanta w dziedzinie Tranpslantologii Klinicznej dotycza{ogonek}ce poste{ogonek}powania profilaktycznego i leczniczego w zakażeniu wirusem cytomegalii u biorców przeszczepów narza{ogonek}dowych. Warszawa, 2010 [in Polish]
3. Hjelmesaeth J, Sagedal S, Hartmann A et al: Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal ransplantation. Diabetologia, 2004; 47(9): 1550-56
4. Sagedal S, Nordal KP, Hartmann A et al: The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant, 2002; 2(9): 850-56
5. Humar A, Gillingham K, Payne WD et al: Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation, 2000; 70(2): 310-13
6. Einollahi B, Lessan-Pezeshki M, Pourfarziani V et al: Does CMV infection increase the incidence of infective endocarditis following kidney transplantation? Ann Transplant, 2009; 14(1): 32-37
7. Yasumoto N, Hara M, Kitamoto Y et al: Cytomegalovirus infection associated with acute pancreatitis, rhabdomyolysis and renal failure. Intern Med, 1992; 31(3): 426-30
8. Fortun J, Martin-Davila P, Pascual J et al., RESITRA Transplant Network: Immunosuppressive therapy and infection after kidney Transplantation. Transpl Infect Dis, 2010; 12(5): 397-405
9. Heering P, Ivens K, Aker S, Grabensee B: Distaltubular acidosis induced by FK506. Clin Trans-plant, 1998; 12(5): 465-71
10. Ozaki KS, Câmara NO, Nogueira E et al: The use of sirolimus in ganciclovir-resistant cytomegalovirus infections In renal transplant recipients. Clin Transplant, 2007; 21(5): 675-80
11. Haririan A, Morawski K, West MS et al: Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection rela-tive to tacrolimus in renal allograft recipients. Clin Transplant, 2007; 21(4): 466-71
12. San Juan R, Aguado JM, Lumbreras C et al.RESITRA Network of the Spanish Study Group of Infection in Transplantation: Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis, 2008; 47(7): 875-82
13. Herraiz M, Beraza N, Solano A et al: Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum Gene Ther, 2003; 14(5): 463-72
14. Navarro JF, Quereda C, Quereda C et al: Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis, 1996; 27(3): 431-34
15. Arenas-Pinto A, Grant AD, Edwards S, Weller IV: Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect, 2003; 79(4): 340-43
16. Walker UA, Bäuerle J, Laguno M et al: Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology, 2004; 39(2): 311-17
17. Sheng WH, Hsieh SM, Lee SC et al: Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan. Int J STD AIDS, 2004; 15(4): 249-53
18. Gérard Y, Melliez H, Mouton Y, Yazdanpanah Y: Mitochondrial cytopathies associated with HIV infection. Rev Neurol (Paris), 2006; 162(1): 62-70